Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120736 | 0.86 | KIF11 (0.77) | KIF11ABCG2TP53 | |
| SCHEMBL17518851 | 0.84 | ADRA1D (0.64) | KIF11EGFRSIGMAR1ABCB1ABCG2 | |
| SCHEMBL3878688 | 0.81 | KIF11 (0.54) | KIF11EGFRABCB1ABCG2MAPKAPK2 | |
| SCHEMBL29188190 | 0.80 | ADRA1D (0.66) | KIF11EGFRSIGMAR1ABCB1ABCG2 | |
| SCHEMBL23875887 | 0.75 | ESR1 (0.69) | KIF11EGFRABCB1ABCG2ADRA1D | |
| SCHEMBL13696261 | 0.74 | KIF11 (0.62) | KIF11ABCG2 | |
| SCHEMBL4028409 | 0.73 | BRD4 (0.52) | KIF11TP53MAPT | |
| SCHEMBL14041951 | 0.73 | KIF11 (0.58) | KIF11SIGMAR1TP53MAPT | |
| SCHEMBL7653569 | 0.72 | PRCP (0.68) | — | |
| SCHEMBL13049423 | 0.72 | KIF11 (0.66) | KIF11EGFRSIGMAR1ABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | disclosed |
| EP-1919475-B1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | ESTEVE LABOR DR (ES) | 2009-03-11 | — | — | EP | disclosed |
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280942-A1 | Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands | HTR6, HTR5A, HTR1B | KIF11 4649/4885EGFR 1578/4885SIGMAR1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.